Compare JMIA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | KURA |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.1M | 841.6M |
| IPO Year | 2018 | 2015 |
| Metric | JMIA | KURA |
|---|---|---|
| Price | $6.82 | $11.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $16.75 | ★ $25.56 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $22.18 | $28.28 |
| Revenue Next Year | $23.26 | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $4.23 | $5.45 |
| 52 Week High | $14.72 | $12.49 |
| Indicator | JMIA | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 58.85 |
| Support Level | $6.45 | $8.72 |
| Resistance Level | $7.59 | $11.40 |
| Average True Range (ATR) | 0.35 | 0.55 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 52.26 | 58.70 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.